About Helixberg

Helixberg is an independent biotech publication providing concise and insightful briefings on major biotech catalysts and portfolio strategies. We are a small team of healthcare professionals who launched this community following long careers in the biotech sector and hedge fund industry.

With billions of dollars invested in groundbreaking pharmaceutical research, the biotech industry is moving at lightning speed. Over our careers we were in awe how little some experts in the traditional media understand to be prepared for major biotech catalysts. Often leading their readers misguided on what really matters and with mediocre returns - one of the major diseases of Biotech investors we aim to cure with this blog.

This publication is our passion with the content supported by our team’s deep experience in analyzing clinical data, valuing biotech firms, and trading biotech stocks.

We are entirely reader-supported, and Helixberg strives to become a go-to resource for investors, researchers, and professionals eager to stay ahead in a rapidly changing biotech field.

We are grateful for each one of our readers and want to make it easy to engage with us. Should you have any questions or idea, please don’t hesitate to contact us at contact@helixberg.com. Together, let’s navigate the frontier of biotech-investing.

Disclaimer

This publication and its authors are not licensed investment professionals. Nothing produced under the Helixberg brand should be construed as investment advice. Do your own research.

Safe Harbor Statement

Please read complete copyright and hedge clause.

Copyright